Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Prostatic Neoplasms 5Urinary Bladder Neoplasms 2Male Urogenital Diseases 2Smoking Cessation 1Pancreatic Neoplasms 1Pain, Postoperative 1Lymphoma, Non-Hodgkin 1Lymphoma, Follicular 1Lung Neoplasms 1Lung Cancer Prevention 1Leiomyoma 1Inflammatory Bowel Diseases 1Duodenal Neoplasms 1Diverticulitis 1Colonic Neoplasms 1Carcinoma, Intraductal, Noninfiltrating 1

Interventions

Gemcitabine 83Cisplatin 59pembrolizumab 28Paclitaxel 21Nivolumab 21Carboplatin 21Cystectomy 20Docetaxel 18durvalumab 17atezolizumab 17Magnetic Resonance Spectroscopy 16Specimen Handling 15Radiotherapy 14avelumab 13Mitomycin 13Sunitinib 12Doxorubicin 12Methotrexate 11Fluorouracil 11Vinblastine 10Filgrastim 7BCG Vaccine 7Sorafenib 6Ipilimumab 6Immunoglobulin G 6Disulfides 6Biopsy 6enfortumab vedotin 5cabozantinib 5Trastuzumab 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Urinary Bladder Neoplasms × Tea × Clear all
NCT04133051 2020-09-25

Perioperative Analgesic Efficiency of Quadratus Lumborum Block vs Epidural in Radical Cystectomy

National Cancer Institute, Egypt

Phase 2 Completed
34 enrolled
Genitourinary

Urinary Bladder Neoplasms, Pain, Postoperative

NCT00088946 2020-07-31

Erlotinib and Green Tea Extract (Polyphenon® E) in Preventing Cancer Recurrence in Former Smokers Who Have Undergone Surgery for Bladder Cancer

Jonsson Comprehensive Cancer Center

Phase 2 Completed
17 enrolled
Genitourinary

Urinary Bladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡